The mostly unrecognized, thought-to-be rare gastrointestinal stromal tumor (GIST) ? now treatable with imatinib (Gleevec) ? is as common as Hodgkin?s disease and chronic myeloid leukemia. A Swedish epidemiologic study histologically reevaluated about 1,000 cases of GIST and found that nearly three quarters of them had been wrongly classified as other tumors, according to a report at the recent American Society of Clinical Oncology Annual Meeting. That translates into an incidence of at least 4,600 new GIST cases annually in the US.
Go to Previous Page
Go to Next Page